Expense guidance includes the expenses related to executing and completing the NEPHRO CRRT registration trial before the end of the year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLPH:
- Talphera files to sell 3.41M shares of common stock for holders
- Talphera, Inc. Earnings Call: Progress Amid Challenges
- Strategic Advancements and FDA Agreement Propel Talphera’s Positive Outlook with Buy Rating
- Talphera Reports 2024 Financial Results and Study Update
- Talphera reports Q4 EPS (7c) vs. (25c) last year